Brighton Jones LLC Acquires 3,909 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Brighton Jones LLC lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 378.8% during the third quarter, HoldingsChannel reports. The firm owned 4,941 shares of the biopharmaceutical company’s stock after purchasing an additional 3,909 shares during the period. Brighton Jones LLC’s holdings in Alnylam Pharmaceuticals were worth $2,253,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock valued at $4,336,064,000 after buying an additional 240,534 shares during the period. Geode Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 3.3% during the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock valued at $779,857,000 after acquiring an additional 75,936 shares in the last quarter. Orbis Allan Gray Ltd raised its stake in shares of Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after acquiring an additional 486,489 shares in the last quarter. Norges Bank purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $662,837,000. Finally, American Century Companies Inc. grew its stake in Alnylam Pharmaceuticals by 1.9% in the second quarter. American Century Companies Inc. now owns 1,793,846 shares of the biopharmaceutical company’s stock worth $584,957,000 after purchasing an additional 33,411 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, November 17th. The shares were sold at an average price of $452.18, for a total value of $5,484,039.04. Following the transaction, the executive vice president directly owned 21,264 shares of the company’s stock, valued at approximately $9,615,155.52. The trade was a 36.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the company’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,727,283.05. Following the transaction, the executive vice president directly owned 54,052 shares in the company, valued at approximately $24,434,206.60. The trade was a 6.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 60,328 shares of company stock worth $27,288,993. 1.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $489.00 target price (up from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Morgan Stanley raised their price target on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research note on Monday, October 6th. Leerink Partners decreased their price objective on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a report on Monday, December 15th. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 8th. Twenty-three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $477.44.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $407.73 on Tuesday. The company has a market capitalization of $53.87 billion, a PE ratio of 1,698.88 and a beta of 0.30. The company has a 50-day simple moving average of $445.05 and a two-hundred day simple moving average of $412.05. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.